SIRO Clinpharm Selects Oracle Health Sciences InForm to Increase Clinical Trial Productivity and Support Global Electronic Data Capture - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
SIRO Clinpharm Selects Oracle Health Sciences InForm to Increase Clinical Trial Productivity and Support Global Electronic Data Capture

Source: Company News Release

To more efficiently conduct and manage electronic data capture (EDC)-based clinical trials on behalf of its clients, SIRO Clinpharm, winner of Frost & Sullivan Indian Clinical Research Organization (CRO) of the year award, 2012 and 2011, recently selected Oracle Health Sciences InForm.

SIRO Clinpharm’s purchase of Oracle Health Sciences InForm extends the company’s investment in Oracle Health Sciences clinical applications, on which it has built its rapidly expanding CRO business.

In addition to selecting Oracle Health Sciences InForm, SIRO Clinpharm gained a competitive advantage by joining the Oracle CRO Advantage Program – a program that provides a framework for driving CRO success with Oracle Health Sciences products through training, sales and marketing support and tools, and regular communications on Oracle products and strategy.

With its sophisticated data review capabilities, Oracle Health Sciences InForm will enable SIRO Clinpharm to have better control over its data, and the company expects to see significant efficiency and productivity gains in data management and remote monitoring.

“SIRO Clinpharm has a long-standing commitment to Oracle Health Sciences clinical applications,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The addition of Oracle Health Sciences InForm will extend SIRO Clinpharm’s clinical data management and EDC capabilities to support a growing number of trials, including global EDC studies, while optimizing its existing Oracle Health Sciences investment.”

Oracle Health Sciences InForm will also provide SIRO Clinpharm flexibility to set targeted source verification strategies that allow for rapid increases or decreases of the source verification workload based on data quality.

Extensive study templates and library management capabilities within Oracle Health Sciences InForm will enable SIRO Clinpharm to accelerate the study-build process and provide sponsors with significantly faster trial implementation.

SIRO Clinpharm will benefit from Oracle Health Sciences InForm’s scalability, performance and multi-language capabilities to deploy global trials.

“As a leading clinical research organization, we looked at the best in class EDC solutions available on the market. We selected Oracle Health Sciences InForm because we believe it clearly stands out from its competitors with outstanding functionality, low total cost of ownership and satisfied end users worldwide," said Gopa Menon, chief executive officer, SIRO Clinpharm.

Oracle Health Sciences InForm is part of a comprehensive portfolio of Oracle Health Sciences Cloud Applications and is powered by the Oracle Health Sciences Cloud to help customers accelerate IT deployments, reduce resources required to maintain IT infrastructure and gain a more predictable IT spending pattern.

SIRO Clinpharm has built a state-of-the-art technology offering that includes Oracle Health Sciences InForm, Oracle Clinical, Oracle Remote Data Capture, Oracle's Siebel Clinical Trial Management System and Oracle Adverse Event Reporting System.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here